Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced a private placement of securities expected to generate approximately $11.5 million in upfront proceeds. The financing, led by Nantahala Capital and involving existing stockholders like ADAR1 Capital Management and Quince's senior management, could potentially raise an additional $10.4 million if the accompanying warrants are fully exercised. Priced at a premium to the last close, the funds are intended for working capital, general corporate purposes, and to support the ongoing Phase 3 NEAT clinical trial in Ataxia-Telangiectasia. Combined with existing resources, this financing is expected to support Quince's operations until mid-2026 or beyond, depending on warrant exercise.